SCHEMBL770628

SCHEMBL770628

O=C(CNC(=S)NC(c1ccccc1)c1ccccc1)N1CCC2CCCCC2C1

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CHRM3 P20309 1/20 0.42
LMNA P02545 1/20 0.42
ALDH1A1 P00352 1/20 0.40
CCR5 P51681 1/20 0.39
KDM1A O60341 2/20 0.39
MAOB P27338 2/20 0.39
EPHX2 P34913 1/20 0.39
TACR1 P25103 6/20 0.39
KMT2A Q03164 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
XIAP P98170 1/20 0.38
BIRC3 Q13489 1/20 0.38
BIRC2 Q13490 1/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15385504 0.87 CHRM3 (0.42) CHRM3LMNAALDH1A1CCR5EPHX2
SCHEMBL771040 0.87 KDM1A (0.48) CHRM3LMNAKDM1AMAOBEPHX2
SCHEMBL770364 0.77 PRMT3 (0.52) LMNAALDH1A1EPHX2KMT2AL3MBTL1
SCHEMBL770629 0.76 TACR1 (0.38) LMNAALDH1A1KDM1AMAOBTACR1
SCHEMBL770475 0.75 CYP3A4 (0.41) ALDH1A1EPHX2KMT2ASMN1; SMN2MEN1
SCHEMBL770992 0.75 PPID (0.51) ALDH1A1KMT2AMEN1
SCHEMBL771341 0.74 PKM (0.43) ALDH1A1EPHX2SMN1; SMN2
SCHEMBL770372 0.74 CACNA2D1 (0.56) LMNAALDH1A1KMT2AMEN1
SCHEMBL771409 0.73 CA12 (0.39) ALDH1A1KMT2ASMN1; SMN2MEN1
SCHEMBL770589 0.73 HSD11B1 (0.37) LMNAALDH1A1KMT2ASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2439202-B1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 SALVAT LAB SA (ES) 2016-04-20 EP disclosed
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 CHRM3 4456/4885LMNA 3155/4885ALDH1A1 144/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 CHRM3 4456/4885LMNA 3116/4885ALDH1A1 142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.